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Abstract
The papain-like protease (PLpro) of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) is a target enzyme for treatment of the 2019 coronavirus infectious disease
(COVID-19). Multiple lead competitive inhibitors to the protease have been previously
discovered, particularly VIR250, HGN1034, and GYX402. Analogs of these ligands were
designed using ChemSketch or Chem3D. The ligand-active site interactions of those unique
ligands were observed and compared using AutoDock Tools, which also computes a predicted
inhibitory constant (Ki). Over the Fall 2020 semester, proficiency in performing several functions
of AutoDock Tools was acquired, and a total of thirteen unique and original compounds
designed based on the aforementioned leads were tested. Three analogs of HGN1034 showed to
have the strongest potential for future research and application: ZDM16 had the closest docking
pose to the lead HGN1034 (Ki ZDM16 = 329.04 nM); ZDM13 and ZDM14 had the lowest
computed inhibitory constants, lower than that of HGN1034 (Ki ZDM14 = 15.96 nM < Ki ZDM13 =
16.45 nM < Ki HGN1034 = 19.78 nM). The limitations of computational chemistry are considered
and rationalized, and prospective follow-up studies and possibilities for future designs of
inhibitors of the SARS-CoV-2 PLpro enzyme are discussed.
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Introduction
Drug design and discovery for the treatment of patients infected with SARS-CoV-2 is a
critical contemporary field of medicinal chemical research, concerning the ubiquitous
COVID-19 pandemic.1-4,6 A potential target enzyme of this coronavirus is the papain-like
protease (PLpro), a tetrameric cysteine protease unique to the virus. Essential for SARS-CoV-2
maturation and proliferation, inactivating this enzyme with an inhibitory small molecule would
effectively suppress the pathogenic activity of the virus within the human body.3,4,6

Figure 1. Lines display of PLpro (from AutoDock Tools)

Medicinal chemists have strived to develop an effective drug targeting PLpro to treat
COVID-19. Since the beginning of the outbreak, several synthetic small molecules have been
designed and tested with PLpro both virtually and in laboratory, and have shown high inhibition
to the enzyme.2,4 These lead compounds are used as the structural basis of designing new drug
molecules with potentially higher potency.3-6 The purpose of this research is to design and
discover PLpro inhibitors with potentially higher inhibition than leads previously tested and
disclosed to the public (available through the Protein Data Bank).
The computational molecular viewing and modeling software, AutoDock Tools
(AutoDock), is used to simulate the docking of an inhibitory ligand in the active site of an
enzyme essential to an infectious virus (or bacterial species). For each “docking,” AutoDock
accounts for the bond lengths, rotatable and non-rotatable bonds, and partial charges of a ligand,
generating a detailed visualization of the position of the small molecule with respect to active
3

site residues. This enables the delineation of specific enzyme-ligand intermolecular interactions.
The software also computes various measurements of binding affinity, particularly the inhibitory
constant (Ki) of a ligand.5,6
The lead PLpro inhibitor most explored in this research was HGN1034, tested by the
Hagen Group of the NIU Department of Chemistry and Biochemistry. The structure of this small
molecule can be slightly modified to test for changes in inhibition. If the docking results of such
an analog suggest similar or even higher inhibition than the lead, it may be produced in an
organic laboratory and then tested with a sample of PLpro in real life. Figure 2 below is the
skeletal formula of HGN1034.

Figure 2. HGN1034

Methods
Ligand design and preparation: Ligands are designed using either of the molecular
drawing softwares, ChemSketch or Chem3D. A new molecule can be created from scratch,
however an existing file of a lead is usually modified. The MDL Molfiles (.mol) of the sketches
are saved from these softwares and then converted to Mol2 format (.mol2), so that they can be
opened in AutoDock. This conversion is carried out using a molecular file conversion software
called OpenBabel. The final step in preparing a ligand for a docking involves AutoDock; the
bond lengths, rotatable and non-rotatable bonds, and partial charges of the ligand are processed
and the ligand is saved as a PDBQT file (.pdbqt). PDBQT stands for Protein Data Bank (PDB),
partial charge (Q), and atom type (T).
Enzyme preparation: For the enzyme, a PDB file (.pdb) containing the complex
three-dimensional structure of the macromolecule is obtained from the PBD itself and opened in
AutoDock. Water molecules are removed and all polar hydrogens are made explicit.
Additionally, the orignal ligand which comes with the PDB file is deleted to vacate the active
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site. The “cleaned” enzyme is then saved as a PDBQT file as well. The four-letter code for the
SARS-CoV-2 PLpro file obtained from the PDB is 6WUU.
The main parameter of a docking is the permutation of a “gridbox,” which is to
encompass an entire active site of the enzyme. The coordinates of a gridbox are specified in all
three dimensions, and the gridbox is saved as a grid parameter file (.gpf). Figure 3 below
displays the one gridbox used to dock inhibitors into PLpro for this research.

Figure 3. Gridbox encompassing one of the four PLpro active sites

Running AutoDock and Comparative Analysis: With PDBQT files of the ligand and
enzyme and a saved gridbox, the docking can then be performed. An algorithm labelled
“autogrid4” is first run to account for the possible interactions of the active site residues
encapsulated in the gridbox. This is followed by the run of a second algorithm labelled
“autodock4,” to generate ten “docking poses” of the ligand inside the active site.
The docking poses of a newly designed ligand are analyzed by visually comparing each
of its poses to the pose of a lead. This is done by superimposing the docking results over a
previously created file of the enzyme with the lead already positioned in the active site. The
enzyme is removed from the view, and the positions of the ligands with respect to the same
active site are compared. For each tested PLpro inhibitor of this project, the docking pose most
closely aligned with the lead was considered the best, and the computed Ki value was recorded
and interpreted. Ligands resulting without a single visually good docking pose were deemed
inadequate for future experimentation.
5

The compound VIR250, which comes pre-docked as a covalently bonded irreversible
inhibitor in the 6WUU enzyme file of PLpro (the molecule has an alkene group which acts as a
Michael acceptor to the active site cysteine residue), was used as the basis for comparison in
determining the best docking poses of VIR250 analogs and two other leads, one of which was
HGN1034, and the other a more recently discovered inhibitor called GYX402. The docking
poses of HGN1034 and GYX402 analogs were then compared with the best poses of their
respective leads.

Results
VIR250 and analogs: Three analogs of VIR250 were designed, substituting the group
alpha to the carbonyl at the tail-end of the peptidomimetic backbone (Figure 4). These
compounds were labelled ZDM1-3, being the first three unique analogs designed for this
research. Along with the analogs, the lead VIR250 was docked into PLpro itself, and compared
with the pose of the same molecule in the unedited PDB file. None of these four ligands resulted
with a similar docking pose, including VIR250 itself as the exact same molecule. Therefore, no
Ki values were recorded for these ligands (Table 1).

Figure 4. Basic structure of VIR250 and analogs.
T1. SAR table for VIR250 and ZDM1-3
Ligand

Formula

MW

R

Ki

VIR250

C23H30N6O6S

518.585

–– OCH3

N/A

ZDM1

C20H26N6O5S

462.522

–– H

N/A

ZDM2

C23H27N7O5S2

545.634

–– C3H2NS

N/A

ZDM3

C21H25F3N6O5S

530.52

–– CF3

N/A

6

HGN1034 and analogs: A total of nine analogs of HGN1034 were designed, ZDM 10-18,
however ZDM16 and ZDM18 are not displayed in Table 2 since they do not have the basic
structure indicated by Figure 5. In Tables 2 and 3, for each ligand with at least one good docking
pose, the number of that pose is indicated to the right of the Ki value in parentheses.

Figure 5. Basic structure of HGN1034 and analogs. Each substituent consists
of an aromatic ring bonded at the 4 position unless marked otherwise.
T2. SAR Table for HGN1034 and ZDM10-15 and ZDM17
Ligand

Formula

MW

R1

R2

Ki

HGN1034

C18H11ClN4O3S

398.822

–– C6H4Cl

–– C6H4NO2

19.78 nM (6)

ZDM10

C19H14N4O3S

378.406

–– C19H14N4O3S

–– C7H7

N/A

ZDM11

C21H18N4O3S

406.457

–– C21H18N4O3S

–– C9H11

N/A

ZDM12

C22H20N4O3S

420.484

–– C22H20N4O3S

–– C4H9

N/A

ZDM13

C17H11N5O3S

365.365

–– C5H4N (4-pyridyl)

–– C6H4NO2

16.45 nM (1)

ZDM14

C17H11N5O3S

365.365

–– C5H4N (3-pyridyl)

–– C6H4NO2

15.96 nM (8)

ZDM15

C17H11N5O3S

365.365

–– C5H4N (2-pyridyl)

–– C6H4NO2

1.37 μM (10)

ZDM17

C17H11ClN4OS

354.813

–– C6H4Cl

–– C5H4N (3-pyridyl)

347.91 nM (6)

For the lead HGN1034, pose 6 was most similar to the pose of VIR250 in the PDB file
(Figure 6), with a Ki of 19.78 nM. The longest carbon chain of the molecule shows a similar
conformation; the length of the HGN1034 molecule follows the length of VIR250 molecule.

Figure 6. Pose 6 of HGN1034 (coral) against pose of
covalently bonded VIR250 (magentain the PLpro active.
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Pose 6 of HGN1034 was then used as the basis for comparison in analyzing the poses of
ZDM10-18. Between ZDM10-15 and ZDM17, the four compounds, ZDM13, ZDM14, ZDM15,
and ZDM17 had good docking poses. ZDM13 (pose 1) and ZDM14 (pose 8) had the lowest Ki
values of 16.45 and 15.96 nM respectively, lower than that of the lead HGN1034. Figure 7 below
displays the docking poses of both ZDM13 and 14 against pose 6 of HGN1034.

Figure 7. Top: Best pose of ZDM13 (cyan) against pose of HGN1034.
Bottom: ZDM14 (violet) against HGN1034 (coral). Both analogs show
relatively close alignment to the lead.
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ZDM16, ZDM18, GYX402, and ZDM20: The structures and Ki values of these last four
compounds are indicated in Figure 8 and Table 3. ZDM16 is not included in Table 2 because
unlike ZDM10-15 and ZDM17, the second six-membered ring is aromatic, forming a pyrimidine
ring instead of a cyclic amide, therefore bearing a hydroxyl instead of a carbonyl. ZDM18 is not
included in Table 2 either since the first and third six-membered rings are para-positioned with
respect to each other and the second ring. Notwithstanding the structural differences between
these two compounds and those indicated in Table 2, ZDM16 and ZDM18 are still considered
HGN1034 analogs, thus their docking poses were compared to pose 6 of HGN1034.
GYX402 is a recently disclosed PLpro inhibitor lead (PDB code: 7D7T) which bears a
naphthyl group. As was done for HGN1034, the docking poses of this ligand were compared to
the pose of the covalently bonded VIR250 in the original PDB file (6WUU). ZDM20 is an
analog of both GYX402 and HGN1034, containing groups from both leads merged together,
particularly the chlorophenyl of HGN1034.

ZDM16

ZDM18

GYX402

ZDM20

Figure 8. Structures of ZDM16, ZDM18, GYX402, and ZDM20.
T3. SAR table for ligands in Figure 8
Ligand

Formula

MW

Ki

ZDM16

C19H12ClN3O2S

381.835

329.04 nM (4)

ZDM18

C20H17ClN4OS

396.893

270.23 nM (8)

GYX402

C27H31N3O2

429.553

86.13 nM (7)

ZDM20

C25H27ClN2O

406.947

217.71 nM (5)
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Between the docking poses of all the unique PLpro inhibitors (thirteen) designed and
tested this semester, pose 4 of ZDM16 was the pose most closely aligned with pose 6 of
HGN1034 (Figure 9), showing a very similar confirmation and high superimposability.
However, despite this high degree of alignment, its computed Ki value of 329.04 nM is much
greater than those of ZDM13 and ZDM14 (16.45 and 15.96 nM).

Figure 9. Pose of ZDM16 (sequoia) against pose of HGN1034.
Compounds show very close alignment.

The best pose of ZDM18 was pose 8 (Figure 10). The fit is similar to those of ZDM13,
ZDM14, and ZDM16, considering the close positions of two of the three six-membered rings,
the cyano group, and the thioether. However, the chlorophenyl group is quite protuberant with
respect to HGN1034.

Figure 10. Pose of ZDM18 (blue) against pose of HGN1034. The
chlorophenyl group is notably protuberant.

10

The docking poses of GYX402 were compared to the lead VIR250, rather HGN1034,
since it is not part of the family of HGN1034 analogs. The naphthyl group of GYX402 in pose 7
of the ligand was positioned similarly to the benzothiazole group of the covalently bonded
VIR250 molecule (Figure 7). When using this pose of GYX402 as the basis of comparison for
analog ZDM20 (pose 5), the naphthyl groups of both ligands have similar positions.

Figure 11. Top: Pose of GYX402 (green) against pose of covalently bonded
VIR250. Bottom: Pose of ZDM20 (orange) against pose of GYX402. The
fused two-ring systems of each ligand have similar positions.
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Discussion
PLpro inhibitors with the strongest potential based on docking results: Of the thirteen
unique and original SARS-CoV-2 papain-like protease inhibitors tested this semester (ZDM1-3,
10-18, 20), the ones which showed the greatest potential to serve as leads or usable drugs in
future COVID-19 drug research were ZDM16, ZDM13, ZDM14. The remarkably close
alignment of pose 4 of ZDM16 with pose 6 of HGN1034 in the PLpro active site (Figure 9)
suggests that the two compounds have similar inhibition. On the contrary, however, the
computed inhibitory constant for ZDM16 of 329.04 nM is about 17 times greater than that of
HGN1034, 19.78 nM, suggesting that the potency of ZDM16 is about 17 times weaker.
Compared to ZDM16, the quality of the results for the docking poses and Ki values of ZDM13
and ZDM14 are the converse. The best poses of ZDM13 and ZDM14 (Figure 7) did not align
with the lead HGN1034 as well as ZDM16 (although they were close), and the computed Ki
values for both ligands are in fact lower that than of HGN1034 (Ki ZDM14 = 15.96 nM < Ki ZDM13 =
16.45 nM < Ki HGN1034 = 19.78 nM).
For these three HGN1034 analogs, the discrepancy between the docking pose and the
computed Ki value is rationalized due to the use of molecular modeling software, rather
producing and testing the compounds in a laboratory in real life. In general, computational
chemistry serves only to predict chemical properties and interactions, including inhibition.
Although the docking poses of ZDM13 and ZDM14 were less similar to HGN1034 than
the pose of ZDM16, this does not necessarily indicate that the poses of ZDM13 and ZDM14 are
worse. The differences in their poses may actually be due to their higher inhibition (lower Ki
values), as computed by AutoDock. It is not absolutely required for the pose of an analog to be
as close as possible to the lead.
Prospective analysis for ligands with the best results: Much of the semester was spent
learning the highly specific and complex basics of using AutoDock Tools. A significant future
area of focus for analyzing the docking results of ZDM13, ZDM14, and ZDM16 would be to
measure a vast multitude of binding distances (Å) between atoms of the ligand and atoms of
active site residues. Measurements taken for each compound individually docked in the PLpro
active site can be compared to rationalize differences in Ki, especially for ZDM16.
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Future inhibitor designs: The compounds VIR250, HGN1034, ZDM16, ZDM13,
ZDM14, and GYX402 could all be used as leads for the design of new SARS-CoV-2 PLpro
inhibitors in the future. Most of the unique and original ligands of this project were designed by
substituting a single functional group. As was done with GYX402 and HGN1034 to design
ZDM20, groups from two or more different leads can be merged together to combine the key
interactions of two or more individual ligands into one new molecule. This would involve a
detailed and precise comparative analysis of the positions of certain groups in the docking poses
of individual ligands.
Conclusive statements: In light of the current coronavirus pandemic, the design and
discovery of inhibitors of the papain-like protease in SARS-CoV-2 is a fast-growing area of
organic and biochemical research in which new ideas and discoveries are being made and
disclosed rather often. With strong resources, such as the Protein Data Bank and previously
collected, and power molecular simulation softwares, such as AutoDock Tools, an extensive
understanding of the ligand-active site interactions of a synthetic small molecule with an enzyme
can be developed. An equipped background in the chemistry of drug design and prowess with
AutoDock Tools is a significant first step in being introduced to the pharmaceutical industry.
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